SKN | Could Bayer’s ERLEADA Lawsuit Disrupt Johnson & Johnson’s Oncology Growth Story?
Stock Analysis Johnson & Johnson faces renewed legal scrutiny after Bayer filed a federal lawsuit accusing the company and its Janssen Biotech unit of falsely promoting the superiority of prostate cancer drug ERLEADA over Bayer’s rival therapy NUBEQA. While the case centers on disputed real-world evidence analyses, its broader implications reach beyond marketing claims. For shareholders, the […]